Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.imlet.2020.10.009 http://scihub22266oqcxt.onion/10.1016/j.imlet.2020.10.009 33161002!7644186!33161002     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Immunol+Lett 2020 ; 228 (ä): 122-128 Nephropedia Template TP {{tp|p=33161002|t=2020. Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab |pdf=|usr=}}{{33161002}} gab.com Text Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab JO: Immunol Lett http://www.kidney.de/pget.php?&tw=1&pmid=33161002 #FOAvip As of October 2020 management of Coronavirus disease 2019 (COVID-19) is based on supportive care and off-label or compassionate-use therapies. On March 2020 tocilizumab - an anti-IL-6 receptor monoclonal antibody - was suggested as immunomodulatory treatment in severe COVID-19 because hyperinflammatory syndrome occurs in many patients similarly to the cytokine release syndrome that develops after CAR-T cell therapy. In our retrospective observational study, 20 severe COVID-19 patients requiring intensive care were treated with tocilizumab in addition to standard-of-care therapy (SOC) and compared with 13 COVID-19 patients receiving only SOC. Clinical respiratory status, inflammatory markers and vascular radiologic score improved after one week from tocilizumab administration. On the contrary, these parameters were stable or worsened in patients receiving only SOC. Despite major study limitations, improvement of alveolar-arterial oxygen gradient as well as vascular radiologic score after one week may account for improved pulmonary vascular perfusion and could explain the more rapid recovery of COVID-19 patients receiving tocilizumab compared to controls. Twit Text FOAVip Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab ????Immunol Lett http://www.kidney.de/pget.php?&tw=1&pmid=33161002 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33161002 #FOAvip English Wikipedia <ref>{{Cite pmid|33161002}}</ref> Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab #MMPMID33161002 Salvati L; Occhipinti M; Gori L; Ciani L; Mazzoni A; Maggi L; Capone M; Parronchi P; Liotta F; Miele V; Annunziato F; Lavorini F; Cosmi L Immunol Lett 2020[Dec]; 228 (ä): 122-128 PMID33161002show ga As of October 2020 management of Coronavirus disease 2019 (COVID-19) is based on supportive care and off-label or compassionate-use therapies. On March 2020 tocilizumab - an anti-IL-6 receptor monoclonal antibody - was suggested as immunomodulatory treatment in severe COVID-19 because hyperinflammatory syndrome occurs in many patients similarly to the cytokine release syndrome that develops after CAR-T cell therapy. In our retrospective observational study, 20 severe COVID-19 patients requiring intensive care were treated with tocilizumab in addition to standard-of-care therapy (SOC) and compared with 13 COVID-19 patients receiving only SOC. Clinical respiratory status, inflammatory markers and vascular radiologic score improved after one week from tocilizumab administration. On the contrary, these parameters were stable or worsened in patients receiving only SOC. Despite major study limitations, improvement of alveolar-arterial oxygen gradient as well as vascular radiologic score after one week may account for improved pulmonary vascular perfusion and could explain the more rapid recovery of COVID-19 patients receiving tocilizumab compared to controls. |*COVID-19 Drug Treatment[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Biomarkers/blood[MESH] |COVID-19/pathology[MESH] |Combined Modality Therapy[MESH] |Critical Care[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Receptors, Interleukin-6/antagonists & inhibitors[MESH] |Respiration/*drug effects[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH] |Time Factors[MESH]Pulmonary vascular improvement in severe COVID-19 patients treated wit(epmc).pdf DeepDyve Pubget Overpricing